EP3823607A4 - ADMINISTRATION OF LEVODOPA AND DOPA DECARBOXYLASE INHIBITOR INTO THE RESPIRATORY TRACT FOR THE TREATMENT OF PARKINSON'S DISEASE - Google Patents

ADMINISTRATION OF LEVODOPA AND DOPA DECARBOXYLASE INHIBITOR INTO THE RESPIRATORY TRACT FOR THE TREATMENT OF PARKINSON'S DISEASE Download PDF

Info

Publication number
EP3823607A4
EP3823607A4 EP19838654.2A EP19838654A EP3823607A4 EP 3823607 A4 EP3823607 A4 EP 3823607A4 EP 19838654 A EP19838654 A EP 19838654A EP 3823607 A4 EP3823607 A4 EP 3823607A4
Authority
EP
European Patent Office
Prior art keywords
levodopa
parkinson
disease
treatment
respiratory tract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19838654.2A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3823607A1 (en
Inventor
John D. Hoekman
Kelsey H. Satterly
Inna DASHEVSKY
Aditya R. DAS
Stephen B. Shrewsbury
Gregory J. DAVIES
Bhavin Y. GAJERA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Impel Pharmaceuticals Inc
Original Assignee
Impel Neuropharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impel Neuropharma Inc filed Critical Impel Neuropharma Inc
Publication of EP3823607A1 publication Critical patent/EP3823607A1/en
Publication of EP3823607A4 publication Critical patent/EP3823607A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A61M15/0035—Piercing means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A61M15/0035—Piercing means
    • A61M15/0036—Piercing means hollow piercing means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/82—Internal energy supply devices
    • A61M2205/8218—Gas operated
    • A61M2205/8225—Gas operated using incorporated gas cartridges for the driving gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2206/00—Characteristics of a physical parameter; associated device therefor
    • A61M2206/10—Flow characteristics
    • A61M2206/20—Flow characteristics having means for promoting or enhancing the flow, actively or passively

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19838654.2A 2018-07-19 2019-07-19 ADMINISTRATION OF LEVODOPA AND DOPA DECARBOXYLASE INHIBITOR INTO THE RESPIRATORY TRACT FOR THE TREATMENT OF PARKINSON'S DISEASE Withdrawn EP3823607A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862700584P 2018-07-19 2018-07-19
US201962820244P 2019-03-18 2019-03-18
PCT/US2019/042689 WO2020018959A1 (en) 2018-07-19 2019-07-19 Respiratory tract delivery of levodopa and dopa decarboxylase inhibitor for treatment of parkinson's disease

Publications (2)

Publication Number Publication Date
EP3823607A1 EP3823607A1 (en) 2021-05-26
EP3823607A4 true EP3823607A4 (en) 2022-04-06

Family

ID=69164787

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19838654.2A Withdrawn EP3823607A4 (en) 2018-07-19 2019-07-19 ADMINISTRATION OF LEVODOPA AND DOPA DECARBOXYLASE INHIBITOR INTO THE RESPIRATORY TRACT FOR THE TREATMENT OF PARKINSON'S DISEASE

Country Status (6)

Country Link
US (3) US11517548B2 (ko)
EP (1) EP3823607A4 (ko)
JP (1) JP2021532098A (ko)
KR (1) KR20210034047A (ko)
CN (1) CN112955134A (ko)
WO (1) WO2020018959A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117503703A (zh) * 2023-11-09 2024-02-06 广州新济药业科技有限公司 一种左旋多巴鼻喷雾剂及其制备方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
WO2012066319A1 (en) * 2010-11-15 2012-05-24 Vectura Limited Apomorphine by pulmonary inhalation, oprionally in combination with l-dopa or a dopamine agonist for use in the treatment of parkinson

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB806284A (en) 1955-11-14 1958-12-23 Chi Ah Lai A new or improved nasal inhaler
US2933259A (en) 1958-03-03 1960-04-19 Jean F Raskin Nozzle head
US3425414A (en) 1965-05-28 1969-02-04 William J La Roche Inhalant dispenser
US3888253A (en) 1972-08-04 1975-06-10 Beecham Group Ltd Device for administration of medicines
FR2224175B1 (ko) 1973-04-04 1978-04-14 Isf Spa
US3971377A (en) 1974-06-10 1976-07-27 Alza Corporation Medicament dispensing process for inhalation therapy
US3908654A (en) 1974-08-02 1975-09-30 Rit Rech Ind Therapeut Dispensing package for a dry biological and a liquid diluent
ZA758010B (en) 1975-11-14 1977-08-31 Syntex Inc Nasal spray adapter
US4095596A (en) 1976-11-26 1978-06-20 Smithkline Corporation Nasal inhaler
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4187985A (en) 1978-12-08 1980-02-12 The Continental Group, Inc. Aerosol valve for barrier type packages
BR8007911A (pt) 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
US4412573A (en) 1981-12-28 1983-11-01 Baxter Travenol Laboratories, Inc. Injection site
US4690332A (en) 1983-11-28 1987-09-01 Nathaniel Hughes Single inlet prepackaged inhaler
WO1985002346A1 (en) 1983-11-28 1985-06-06 Vortran Corporation Gas-powered nebulizer
EP0194258A1 (en) 1984-09-18 1986-09-17 Vortran Corporation All purpose nebulizer
US4896832A (en) 1987-09-07 1990-01-30 Bespak Plc Dispensing apparatus for metered quantities of pressurised fluid
EP0315964B1 (en) * 1987-11-11 1993-01-07 Laboratoires Pharmascience A novel pharmaceutical composition comprising exifone and water-soluble polymer
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
IL111254A (en) 1990-06-14 1998-10-30 Rhone Poulenc Rorer Ltd Powder inhalers
DE4038049C2 (de) 1990-11-29 1994-12-01 Anschuetz & Co Gmbh Implantierbare Infusionspumpe
US5331954A (en) 1990-12-21 1994-07-26 Novo Nordisk A/S Device for nasal delivery of liquid medications
IT1249600B (it) 1991-02-21 1995-03-09 Elettro Plastica Spa Erogatore nasale di sostanze farmaceutiche nebulizzate
US6681767B1 (en) 1991-07-02 2004-01-27 Nektar Therapeutics Method and device for delivering aerosolized medicaments
IT1250691B (it) 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
GB9125699D0 (en) 1991-12-03 1992-01-29 Glaxo Group Ltd Device
US5819730A (en) 1993-06-09 1998-10-13 Glaxo Wellcome Australia Ltd. Device for administering pharmaceutical substances
US5349947A (en) 1993-07-15 1994-09-27 Newhouse Michael T Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow
US5516006A (en) 1993-07-30 1996-05-14 Meshberg; Philip Nasal dispenser
US5398850A (en) 1993-08-06 1995-03-21 River Medical, Inc. Gas delivery apparatus for infusion
IT1266794B1 (it) 1993-11-09 1997-01-21 Faustino Ballini Dispositivo a doccia micronizzata per il lavaggio delle cavita' nasali e limitrofe
EP0759744B1 (en) 1994-05-13 2001-10-17 Aradigm Corporation Narcotic containing aerosol formulation
US5435282A (en) 1994-05-19 1995-07-25 Habley Medical Technology Corporation Nebulizer
JP3372105B2 (ja) 1994-05-26 2003-01-27 株式会社日立ユニシアオートモティブ 吸入式投薬器
US5901703A (en) 1995-02-06 1999-05-11 Unisia Jecs Corporation Medicine administering device for nasal cavities
DE19518580A1 (de) 1995-05-20 1996-11-21 Thomas Ossinger Lötbadtiegel
JPH08322934A (ja) 1995-05-29 1996-12-10 Unisia Jecs Corp 鼻腔用投薬器
DE19523516C1 (de) 1995-06-30 1996-10-31 Asta Medica Ag Inhalator zum Verabreichen von Medikamenten aus Blisterpackungen
US5823183A (en) 1995-08-02 1998-10-20 Innovative Devices Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament
GB9516984D0 (en) 1995-08-18 1995-10-18 Pharmasol Ltd Spray applicator
IE77523B1 (en) 1995-09-11 1997-12-17 Elan Med Tech Medicament delivery device
US5711488A (en) 1995-10-13 1998-01-27 The Procter & Gamble Company High pressure swirl atomizer
US6678553B2 (en) 1995-11-21 2004-01-13 Intraabrain International Nv Device for enhanced delivery of biologically active substances and compounds in an organism
US5797390A (en) 1996-03-06 1998-08-25 Mcsoley; Thomas E. Nasal inhaler having a directed spray pattern
AUPN976496A0 (en) 1996-05-10 1996-05-30 Glaxo Wellcome Australia Ltd Unit dose dispensing device
US6595202B2 (en) 1996-05-13 2003-07-22 Universidad De Sevilla Device and method for creating aerosols for drug delivery
DE19622124A1 (de) 1996-06-01 1997-12-04 Alfred Von Schuckmann Gerät zum Aufbringen von Flüssigkeiten
WO1997048496A1 (en) 1996-06-21 1997-12-24 Hughes Technology Group L.L.C. Micro-atomizing device
US5906198A (en) 1996-07-16 1999-05-25 Flickinger; William J. Nasal nebulizer
US7033598B2 (en) 1996-11-19 2006-04-25 Intrabrain International N.V. Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
US6410046B1 (en) 1996-11-19 2002-06-25 Intrabrain International Nv Administering pharmaceuticals to the mammalian central nervous system
DE19704849B4 (de) 1997-02-08 2011-02-17 Ing. Erich Pfeiffer Gmbh Austragvorrichtung für Medien
IS4516A (is) 1997-07-01 1999-01-02 Gizurarson Sveinbjörn Nýtt lyfjaform
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
GB9719775D0 (en) 1997-09-18 1997-11-19 Glaxo Group Ltd Device
US5954696A (en) 1997-12-15 1999-09-21 B. Braun Medical, Inc. Pressure infusion pump
US7335186B2 (en) 1998-03-13 2008-02-26 Alexander George Brian O'Neil Patient controlled drug delivery device
US6113078A (en) 1998-03-18 2000-09-05 Lytesyde, Llc Fluid processing method
US6062213A (en) 1998-06-16 2000-05-16 Fuisz Technologies Ltd. Single unit dose inhalation therapy device
JP4570251B2 (ja) 1998-07-24 2010-10-27 ヤゴテック アーゲー 医薬用エーロゾル製剤
FR2782024B1 (fr) 1998-08-04 2000-10-13 Valois Sa Tete de distribution et dispositif de distribution de produit fluide comportant une telle tete
GB2345010B (en) 1998-12-17 2002-12-31 Electrosols Ltd A delivery device
US6294153B1 (en) 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
AU2862200A (en) 1999-01-27 2000-08-18 Bruce H. Levin Compositions, kits, apparatus, and methods for inhibiting cerebral neurovasculardisorders and muscular headaches
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0121568D0 (en) 2001-09-06 2001-10-24 Optinose As Nasal delivery device
ES2439274T3 (es) 1999-03-03 2014-01-22 Optinose As Dispositivo de administración nasal
GB0114272D0 (en) 2001-06-12 2001-08-01 Optinose As Nasal delivery device
AU3751700A (en) 1999-03-17 2000-10-04 Emsar, Inc. Apparatus and method for dispensing a medicinal spray
EE200100500A (et) 1999-03-26 2003-02-17 Pozen Inc. Suure võimsusega dihüdroergotamiini kompositsioonid
DE19944209A1 (de) 1999-09-15 2001-03-22 Pfeiffer Erich Gmbh & Co Kg Spender zum ggf. zerstäubten Ausbringen eines insbesondere flüssigen Mediums aus einem Behältnis
US6382204B1 (en) 1999-10-14 2002-05-07 Becton Dickinson And Company Drug delivery system including holder and drug container
ATE257399T1 (de) 1999-10-14 2004-01-15 Becton Dickinson Co Nasales verabreichungsgerät mit zerstäuberdüse
US6367471B1 (en) 1999-11-01 2002-04-09 Sheffield Pharmaceuticals, Inc. Internal vortex mechanism for inhaler device
US6810872B1 (en) 1999-12-10 2004-11-02 Unisia Jecs Corporation Inhalant medicator
US6302101B1 (en) 1999-12-14 2001-10-16 Daniel Py System and method for application of medicament into the nasal passage
EP1712222A3 (en) * 1999-12-23 2012-06-20 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
US6585957B1 (en) 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6540983B1 (en) 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6644305B2 (en) 2000-04-14 2003-11-11 Trudell Medical International Nasal inhaler
GB0015309D0 (en) 2000-06-21 2000-08-16 Djupesland Per G Apparatus
IT1317998B1 (it) 2000-06-26 2003-07-21 Medical Internat Licensing N V Valvola erogatrice per spray nasale.
IT1318646B1 (it) 2000-07-26 2003-08-27 Medical Internat Licensing N V Ugello pr somministrazioni e lavaggi nasali.
EP2255806A3 (en) 2000-07-31 2011-06-29 Nycomed Danmark ApS Fentanyl composition for nasal administration
CA2359813C (en) 2000-10-24 2008-04-22 Richard L. Jones Nicotine mucosal spray
US6644309B2 (en) 2001-01-12 2003-11-11 Becton, Dickinson And Company Medicament respiratory delivery device and method
ZA200306564B (en) 2001-02-26 2004-10-15 Optinose As Nasal devices.
GB0109001D0 (en) 2001-04-10 2001-05-30 Glaxo Group Ltd Dispenser
GB0109002D0 (en) 2001-04-10 2001-05-30 Glaxo Group Ltd Dispenser
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
EP1279404A1 (en) 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
US7231919B2 (en) 2001-09-28 2007-06-19 Kurve Technology, Inc. Particle dispersion device for nasal delivery
GB2380410B (en) 2001-10-05 2003-11-19 Alchemy Healthcare Ltd Apparatus for the nasal or oral delivery of a medicament
US7021561B2 (en) 2001-12-18 2006-04-04 Becton, Dickinson And Company Spray device and method
GB0204829D0 (en) 2002-03-01 2002-04-17 Glaxo Group Ltd A fluid dispensing device
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
EP1531798B1 (en) * 2002-03-20 2012-06-06 Civitas Therapeutics, Inc. Pulmonary delivery for levodopa
GB0207422D0 (en) 2002-03-28 2002-05-08 Optinose As Nasal devices
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
CA2485217C (en) 2002-05-06 2012-05-01 Thomas Jefferson University Insulin-associated peptides with effects on cerebral health
US8122881B2 (en) 2002-05-09 2012-02-28 Kurve Technology, Inc. Particle dispersion device for nasal delivery
US7220457B2 (en) 2002-06-06 2007-05-22 Anderson Steven R Air atomizing assembly and method and system of applying an air atomized material
GB0215270D0 (en) 2002-07-02 2002-08-14 Optinose As Nasal devices
GB0215904D0 (en) 2002-07-09 2002-08-21 Team Holdings Uk Ltd Drug delivery system and method
GB0217198D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicament dispenser
GB0309354D0 (en) 2003-04-24 2003-06-04 Glaxo Group Ltd Nozzle for a nasal inhaler
DE10321902A1 (de) 2003-05-06 2004-12-09 Ing. Erich Pfeiffer Gmbh Austragvorrichtung für zumindest ein Medium
GB0319119D0 (en) 2003-08-14 2003-09-17 Optinose As Delivery devices
GB0320171D0 (en) 2003-08-28 2003-10-01 Optinose As Delivery devices
AU2004270174B2 (en) 2003-08-29 2010-05-20 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
US8001963B2 (en) 2003-09-05 2011-08-23 Kurve Technology, Inc. Integrated nebulizer and particle dispersion chamber for nasal delivery of medicament to deep nasal cavity and paranasal sinuses
JP2007523050A (ja) 2003-09-17 2007-08-16 カイアズマ・リミテッド 生物学的障壁を通した透過を容易にすることのできる組成物
GB0322284D0 (en) 2003-09-23 2003-10-22 Glaxo Group Ltd Medicament dispenser
US8134010B2 (en) * 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
US7832394B2 (en) 2004-12-22 2010-11-16 Schechter Alan M Apparatus for dispensing pressurized contents
GB0503738D0 (en) 2005-02-23 2005-03-30 Optinose As Powder delivery devices
EP1907444B1 (en) 2005-04-01 2009-08-19 Intezyne Technologies Incorporated Polymeric micelles for drug delivery
GB0515592D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Nozzle for a nasal inhaler
DK1912626T3 (en) * 2005-08-08 2016-08-01 Abbvie Deutschland Dosage forms with improved bioavailability
US20070074722A1 (en) 2005-09-21 2007-04-05 Kurve Technology, Inc. Medicament delivery control, monitoring, and reporting system and method
MX2008006204A (es) 2005-11-11 2008-10-17 Aurogen Inc Metodo para tratar por medio de la administracion de insulina la enfermedad o el trastorno del sistema nervioso central asociado con el encogimiento de tejido o atrofia.
WO2007064657A1 (en) 2005-11-29 2007-06-07 Alza Corporation Nasal delivery device for the delivery of a substance to the olfactory region
US20070202051A1 (en) 2006-02-10 2007-08-30 Pari Gmbh Aerosols for sinunasal drug delivery
GB2434990B (en) 2006-02-14 2010-12-01 Optinose As Delivery device and method
GB0604444D0 (en) 2006-03-06 2006-04-12 Optinose As Nasal devices
GB0605799D0 (en) 2006-03-23 2006-05-03 Optinose As Nasal delivery devices
US7841338B2 (en) 2006-04-13 2010-11-30 Boehringer Ingelheim International Gmbh Dispensing device
US7425542B2 (en) * 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
GB2440316A (en) 2006-07-25 2008-01-30 Optinose As Nasal inhaler with scrubber
CA2698137A1 (en) 2006-08-30 2008-03-06 Kurve Technology, Inc. Aerosol generating and delivery device
FR2908753B1 (fr) 2006-11-16 2011-11-11 Becton Dickinson France Dispositif pour delivrer automatiquement des doses successives de produit
WO2008067254A2 (en) 2006-11-27 2008-06-05 Abbott Respiratory Llc Nasal drug delivery device and method
GB0623732D0 (en) 2006-11-28 2007-01-10 Optinose As Powder delivery devices
GB0623728D0 (en) 2006-11-28 2007-01-10 Optinose As Delivery devices
EP2120875B1 (en) 2007-02-11 2018-07-11 Map Pharmaceuticals Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
GB2448193A (en) 2007-04-05 2008-10-08 Optinose As Nasal delivery device
US8530463B2 (en) 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
WO2008154337A1 (en) 2007-06-08 2008-12-18 Healthpartners Research Foundation Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
GB0719299D0 (en) 2007-10-03 2007-11-14 Optinose As Nasal delivery devices
US20110053859A1 (en) 2007-10-10 2011-03-03 The U. S. Government Respresented by the Department of Veterans Affairs Methods to reduce the effects of sleep deprivation
WO2009085306A1 (en) * 2007-12-28 2009-07-09 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
CN101980738A (zh) 2008-02-07 2011-02-23 华盛顿大学 圆周气雾设备
CA2715302A1 (en) 2008-02-15 2009-08-20 Timothy Sean Immel Aerosol therapy device with high frequency delivery
US8517026B2 (en) 2008-02-25 2013-08-27 Adva Beck Amon Nasal inserts
NO329804B1 (no) 2009-02-09 2010-12-20 Fmc Kongsberg Subsea As Kobling for bruk i et stigeror, stigeror med en slik kobling og fremgangsmate for a oke operasjonsvinduet til et stigeror
KR101220182B1 (ko) * 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
WO2010131486A1 (en) 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
US8839790B2 (en) 2009-07-29 2014-09-23 Adva Beck Arnon Nasal inserts
US8408427B2 (en) 2009-09-07 2013-04-02 Mk International Pty Ltd Single dose nasal spray pump
WO2011047412A1 (en) 2009-10-22 2011-04-28 The Heart Research Institute Ltd Tyrosine and l-dopa for reducing l-dopa incorporation into proteins
US8925544B2 (en) 2009-12-08 2015-01-06 Medinvent, Llc Portable nebulizer device
WO2011143721A1 (en) * 2010-05-21 2011-11-24 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating neurodegenerative disorders
US9180264B2 (en) 2010-11-29 2015-11-10 Sanofi-Aventis Deutschland Gmbh Medicated module for an inhaler
CN103917265B (zh) 2011-03-03 2017-02-15 英倍尔药业股份有限公司 鼻药递送装置
JP6645735B2 (ja) 2011-05-09 2020-02-14 インペル ニューロファーマ インコーポレイテッド 鼻薬送達用ノズル
US8987199B2 (en) 2011-06-15 2015-03-24 Nerve Access, Inc. Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders
DE102012201178B3 (de) 2012-01-27 2013-02-14 Aptar Radolfzell Gmbh Düseneinheit und Spender mit einer solchen
CA2876203A1 (en) * 2012-06-11 2013-12-19 Psychogenics, Inc. Use of eltoprazine in the treatment of motor and movement disorders associated with the treatment of parkinson's disease
WO2014031964A1 (en) 2012-08-24 2014-02-27 Vr1, Inc. Composition for the treatment of migraine headaches
MX2015005038A (es) * 2012-10-22 2015-12-01 Civitas Therapeutics Inc Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson.
DE102013100473A1 (de) 2013-01-17 2014-07-17 Seho Systemtechnik Gmbh Verfahren und Vorrichtung zum Reinigen einer Lötdüse
EP2991713B1 (en) 2013-04-28 2019-06-19 Impel Neuropharma Inc. Medical unit dose container
EP3049059B1 (en) 2013-09-24 2021-11-03 Satsuma Pharmaceuticals, Inc. Intranasal dhe formulation for the treatment of headache
US20160296591A1 (en) * 2013-10-11 2016-10-13 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of bdnf-related conditions
RU2545734C1 (ru) 2014-01-31 2015-04-10 Открытое акционерное общество "Всероссийский Научный Центр Молекулярной Диагностики и Лечения" (ОАО "ВНЦМДЛ) Лекарственный препарат для лечения болезни паркинсона
US9603905B2 (en) 2014-03-13 2017-03-28 The Research Foundation For Mental Hygiene, Inc Intranasal insulin administration for the minimization of anesthesia-induced memory loss
WO2015163840A1 (en) 2014-04-21 2015-10-29 Civitas Therapeutics, Inc. Rapid relief of motor fluctuations in parkinson's disease
WO2015179490A1 (en) * 2014-05-21 2015-11-26 Stemnion, Inc. Treatment of diseases and conditions caused by increased vascular permeability
CA2989884A1 (en) * 2015-07-09 2017-01-12 Insmed Incorporated Compositions and methods for treating lung diseases and lung injury
US10555922B2 (en) * 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
EP3442538A4 (en) 2016-04-04 2019-11-20 Sinopia Biosciences, Inc. TREATMENT OF EXTRAPYRAMIDAL SYNDROME WITH TRAPIDILE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
WO2012066319A1 (en) * 2010-11-15 2012-05-24 Vectura Limited Apomorphine by pulmonary inhalation, oprionally in combination with l-dopa or a dopamine agonist for use in the treatment of parkinson

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOWEN P: "Particle Size Distribution Measurement from Millimeters to Nanometers and from Rods to Platelets", JOURNAL OF DISPERSION SCIENCE AND TECHNOLOGY, TAYLOR AND FRANCIS GROUP, NEW YORK, NY, US, vol. 23, no. 5, 1 January 2002 (2002-01-01), pages 631 - 662, XP009102859, ISSN: 0193-2691, DOI: 10.1081/DIS-120015368 *
KIM T K ET AL: "Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER AMSTERDAM, NL, vol. 38, no. 5, 8 December 2009 (2009-12-08), pages 525 - 532, XP026764334, ISSN: 0928-0987, [retrieved on 20091003], DOI: 10.1016/J.EJPS.2009.09.019 *
SARAL A M ET AL: "Bootstrap confidence interval approach to compare bioavailability of nasal levodopa microspheres vs intranasal levodopa carbidopa formulation in brain", JOURNAL OF THE INDIAN CHEMICAL SOCIETY, INDIAN CHEMICAL SOCIETY, IN, vol. 92, no. 4, 1 January 2015 (2015-01-01), pages 514 - 517, XP009529476, ISSN: 0019-4522 *

Also Published As

Publication number Publication date
EP3823607A1 (en) 2021-05-26
CN112955134A (zh) 2021-06-11
WO2020018959A1 (en) 2020-01-23
US11517548B2 (en) 2022-12-06
US20220233486A1 (en) 2022-07-28
KR20210034047A (ko) 2021-03-29
US20230301955A1 (en) 2023-09-28
US11690819B2 (en) 2023-07-04
US20200046667A1 (en) 2020-02-13
JP2021532098A (ja) 2021-11-25

Similar Documents

Publication Publication Date Title
IL274648A (en) Promote new catecholamine drugs for use in the treatment of Parkinson's disease
JOP20200033A1 (ar) تركيبات حمض أميني لمعالجة مرض كبدي
WO2011091213A3 (en) Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
SG11202011296VA (en) Compositions and methods for the treatment of parkinson's disease
WO2011056240A3 (en) Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
MX2016011837A (es) Composiciones de inhibidores de la dopa decarboxilasa.
EP3607952A4 (en) USE OF CARRIMYCIN AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND / OR PREVENTION OF TUMORS
SG11202107497XA (en) Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors
IL282562A (en) Composition and use for the treatment of parkinson's disease and related disorders
EP3632440A4 (en) USE OF LIGASTROZIN NITRONE DERIVATIVES FOR THE PREVENTION AND TREATMENT OF DIABETIC COMPLICATION DISEASES
ZA202007834B (en) Compositions comprising amino acids for use in the prevention and treatment of liver diseases
IL283654A (en) Decarboxylase inhibitors for the treatment of Parkinson's disease
EP3823607A4 (en) ADMINISTRATION OF LEVODOPA AND DOPA DECARBOXYLASE INHIBITOR INTO THE RESPIRATORY TRACT FOR THE TREATMENT OF PARKINSON'S DISEASE
EP3982819A4 (en) METHODS FOR THE ASSESSMENT AND TREATMENT OF ALZHEIMER'S DISEASE AND THEIR APPLICATIONS
ZA202101489B (en) Compositions and methods for the treatment of parkinson's disease
WO2016049580A3 (en) Inhibitors of nf kappa-b activity for treatment of diseases and disorders
EP4031113A4 (en) THERAPEUTIC USES AND METHODS OF ADMINISTRATION OF VISCOUS COMPOSITIONS DURING PRE- AND POST-SURGICAL PERIODS, FOR THE TREATMENT OF SENSITIVE DISEASES OF THE EAR, NOSE AND THROAT
EP3818981A4 (en) SYNERGIC PHARMACEUTICAL COMBINATION OF THE ACTIVE ENANTIOMER S-KETOROLAC AND GABAPENTIN FOR THE TREATMENT OF NEUROPATHIC PAIN
EP3777849A4 (en) PHARMACEUTICAL COMPOSITION, COMPRISING POLMACOXIB AND PREGABALIN, FOR THE TREATMENT OF PAIN
GB201800912D0 (en) Compositions for the treatment of a disease of the urinary tract and treatment of a disease involving the intracellular delivery of the particle
EP3920924A4 (en) LOW DOSE PRIDOPIDINE FOR TREATING PARKINSON'S DISEASE AND OTHER PARKINSONISM-ASSOCIATED DISEASES
EP3965886A4 (en) NASAL SPRAY COMPOSITIONS AND RELATED METHODS OF TREATMENT
EP3815691A4 (en) USE OF A COMPOSITION OF D-MANNURONIC ACID IN THE TREATMENT OF PARKINSON'S DISEASE
EP3989939A4 (en) POLYMER CONJUGATE OF LEVODOPA, CORRESPONDING FORMULATIONS, AND THEIR USES FOR THE TREATMENT OF PARKINSON'S DISEASE
EP3846792A4 (en) METHODS AND COMPOSITIONS FOR TREATING ASTHMA OR PARKINSON'S DISEASE

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210201

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220304

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/48 20060101ALI20220228BHEP

Ipc: A61K 9/14 20060101ALI20220228BHEP

Ipc: A61K 47/18 20170101ALI20220228BHEP

Ipc: A61K 31/198 20060101ALI20220228BHEP

Ipc: A61K 31/133 20060101AFI20220228BHEP

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IMPEL PHARMACEUTICALS INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230725

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240206